AION Labs

Incubator Active Rehovot, Israel Est. 2021
Visit website ↗ LinkedIn
Last updated 2026-06-18
Portfolio
8
in our dataset
Rounds participated
8
Rounds led
3
Rounds' value
$19.3M
total disclosed, rounds participated
Stages
Pre-Seed, A Round, Seed

About

AION Labs is a venture studio dedicated to building and investing in startups that leverage AI to revolutionize drug discovery and development. It is a unique partnership formed by AstraZeneca, Merck, Pfizer, Teva, the Israel Biotech Fund, Amiti Ventures, and AWS, supported by the Israeli Innovation Authority.

By combining global pharmaceutical expertise with cutting-edge AI, AION Labs' unique venture studio model creates an optimal environment for startups by fostering cross-industry partnerships, funding opportunities, and offering unparalleled access to pharma R&D expertise and data.

In just three years, AION Labs has launched nine companies and built a proven venture-formation engine. The portfolio has executed multiple pilots with its founding pharma partners, as well as additional collaborations with other pharma and biotech organizations, generating meaningful scientific progress across the drug R&D value chain. The model has also attracted strong market validation, including multiple up-rounds, significant follow-on investment from leading global venture funds.

Portfolio · 8

Promise Bio
Epiproteomic Analyses on standard Mass-Spectrometry Data
1 round $8.3M committed Latest: 2024-12
Cellyrix Therapeutics
TargetingTumor Heterogeneity
Led ★ 1 round Latest: 2024-12
Cassidy Bio
Driving Genome Editing Therapeutics Forward
1 round $8.0M committed Latest: 2024-08
ProPhet
AI-driven Drug Discovery
1 round Latest: 2024-07
CombinAble.AI
Tailored Antibody Optimization
Led ★ 1 round Latest: 2024-03
TenAces Biosciences
Molecular Glue Therapeutics
1 round Latest: 2024-01
DenovAI Biotech
Dynamic Protein Design
Led ★ 1 round $1.0M committed Latest: 2023-02
OMEC.AI
Predicting Drug Success in Clinical Trials
1 round $2.0M committed Latest: 2022-09

Investment activity

1 portfolio exit on record.

Portfolio by sector

Health Tech & Life Sciences8

Q&A

What is AION Labs' primary focus as an investor?
AION Labs is a venture studio focused on building and investing in startups that leverage AI to revolutionize drug discovery and development, primarily within the Health Tech & Life Sciences sector.
Which companies are among AION Labs' most recent portfolio additions?
In December 2024, AION Labs added Cassidy Bio, which raised $8M in Seed funding, and ProPhet, which secured $1M in Pre-Seed funding, to its portfolio.
Has AION Labs had any notable exits recently?
Yes, in January 2026, AION Labs saw an exit with the acquisition of CombinAble.AI by insitro.
What is AION Labs' investment stage preference?
AION Labs primarily invests in Pre-Seed, Seed, and A Round stages. According to startupim data, they have made 3 Pre-Seed investments and 4 Seed investments.
Who are the key executives at AION Labs?
The key executives at AION Labs include Mati Gill as CEO, Sharon Gour Arie as COO, and Dr. Yair Benita as CTO.
What is the geographic focus of AION Labs' operations?
AION Labs is headquartered in Rehovot, Israel, and is supported by the Israeli Innovation Authority.
Can you name another recent investment by AION Labs?
In August 2024, AION Labs invested in TenAces Biosciences, a Seed-stage company focused on Molecular Glue Therapeutics.
What kind of partners support AION Labs?
AION Labs operates as a unique partnership formed by AstraZeneca, Merck, Pfizer, Teva, the Israel Biotech Fund, Amiti Ventures, and AWS, with support from the Israeli Innovation Authority.
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)